{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T18:24:15Z","timestamp":1785781455223,"version":"3.56.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010428","name":"Innovation and Technology Fund","doi-asserted-by":"publisher","award":["Seed Programme- ITS\/184\/21"],"award-info":[{"award-number":["Seed Programme- ITS\/184\/21"]}],"id":[{"id":"10.13039\/501100010428","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Innovation and Technology Commission"},{"name":"Government of Hong Kong Special Administrative Region"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Hypothesis<\/jats:title>\n                    <jats:p>Patients with schizophrenia spectrum disorders have elevated cardiovascular risk with obesity and deranged metabolic profiles associated with antipsychotic usage, bearing significant tolls on chronic morbidity and mortality. The present study aims to evaluate the efficacy and tolerability of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in improving weight control and metabolic profile in atypical antipsychotics-treated patients with schizophrenia spectrum disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Design<\/jats:title>\n                    <jats:p>This double-blind, randomized, placebo-controlled trial studied overweight or obese adults with schizophrenia spectrum disorders (non-diabetic or pre-diabetic) who were taking atypical antipsychotics. Participants recruited from a specialist clinic of a regional public service were randomized to receive empagliflozin or placebo for 16\u00a0weeks, in combination with standardized lifestyle intervention through psychoeducation. The primary outcomes were changes in body weight and body mass index (BMI). Changes in other metabolic parameters were examined as secondary outcomes. Linear mixed models were used to study the differences in outcomes between the active and placebo arms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 52 patients undergoing randomization, the SGLT2i group had significant reductions in body weight (\u22121.53\u00a0kg; 95% CI, \u22122.60 to \u22120.47), BMI (\u22120.53\u00a0kg\/m2; 95% CI, \u22120.91 to \u22120.15), fasting glucose (\u22120.40\u00a0mmol\/L; 95% CI, \u22120.65 to \u22120.15), and glycated hemoglobin A1c (\u22120.11%; 95% CI, \u22120.21 to \u22120.02) compared with the placebo group (P-values &amp;lt;.05). Adverse events and dropout rates were similar between the 2 groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The combined approach of empagliflozin and lifestyle intervention improved weight control and glucose metabolism among patients with schizophrenia spectrum disorders receiving atypical antipsychotics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/schbul\/sbag050","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T12:38:19Z","timestamp":1773751099000},"source":"Crossref","is-referenced-by-count":1,"title":["Effects of Empagliflozin and Lifestyle Intervention on Improving Body Weight and Other Metabolic Parameters in Atypical Antipsychotics-treated Patients with Schizophrenia Spectrum Disorders\u2014A Double-blind Randomized Placebo-controlled Trial"],"prefix":"10.1093","volume":"52","author":[{"given":"Sin-Ying","family":"Wong","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, The Chinese University of Hong Kong , c\/o Ground Floor, Multicentre, Tai Po Hospital, 9 Chuen On Road, Tai Po, New Territories, Hong Kong SAR ,","place":["China"]},{"name":"Department of Psychiatry, Tai Po Hospital\/Alice Ho Miu Ling Nethersole Hospital\/North District Hospital, New Territories East Cluster, Hospital Authority , Hong Kong SAR ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheung-Chun","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, The Chinese University of Hong Kong , c\/o Ground Floor, Multicentre, Tai Po Hospital, 9 Chuen On Road, Tai Po, New Territories, Hong Kong SAR ,","place":["China"]},{"name":"Department of Psychiatry, Tai Po Hospital\/Alice Ho Miu Ling Nethersole Hospital\/North District Hospital, New Territories East Cluster, Hospital Authority , Hong Kong SAR ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Man Flora","family":"Mo","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, The Chinese University of Hong Kong , c\/o Ground Floor, Multicentre, Tai Po Hospital, 9 Chuen On Road, Tai Po, New Territories, Hong Kong SAR ,","place":["China"]},{"name":"Department of Psychiatry, Tai Po Hospital\/Alice Ho Miu Ling Nethersole Hospital\/North District Hospital, New Territories East Cluster, Hospital Authority , Hong Kong SAR ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9001-5158","authenticated-orcid":false,"given":"Joshua","family":"Tsoh","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, The Chinese University of Hong Kong , c\/o Ground Floor, Multicentre, Tai Po Hospital, 9 Chuen On Road, Tai Po, New Territories, Hong Kong SAR ,","place":["China"]},{"name":"Department of Psychiatry, Shatin Hospital\/Prince of Wales Hospital, New Territories East Cluster, Hospital Authority , Hong Kong SAR ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing-Ho Oscar","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, The Chinese University of Hong Kong , c\/o Ground Floor, Multicentre, Tai Po Hospital, 9 Chuen On Road, Tai Po, New Territories, Hong Kong SAR ,","place":["China"]},{"name":"Department of Psychiatry, Tai Po Hospital\/Alice Ho Miu Ling Nethersole Hospital\/North District Hospital, New Territories East Cluster, Hospital Authority , Hong Kong SAR ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsun-Ming","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, The Chinese University of Hong Kong , c\/o Ground Floor, Multicentre, Tai Po Hospital, 9 Chuen On Road, Tai Po, New Territories, Hong Kong SAR ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sau-Man Sandra","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, The Chinese University of Hong Kong , c\/o Ground Floor, Multicentre, Tai Po Hospital, 9 Chuen On Road, Tai Po, New Territories, Hong Kong SAR ,","place":["China"]},{"name":"Department of Psychiatry, Tai Po Hospital\/Alice Ho Miu Ling Nethersole Hospital\/North District Hospital, New Territories East Cluster, Hospital Authority , Hong Kong SAR ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hei-Ming","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, The Chinese University of Hong Kong , c\/o Ground Floor, Multicentre, Tai Po Hospital, 9 Chuen On Road, Tai Po, New Territories, Hong Kong SAR ,","place":["China"]},{"name":"Department of Chemical Pathology, Faculty of Medicine, The Chinese University of Hong Kong , Sha Tin, Hong Kong SAR ,","place":["China"]},{"name":"Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong , Sha Tin, Hong Kong SAR ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"key":"2026050903565267000_ref1","doi-asserted-by":"publisher","first-page":"102294","DOI":"10.1016\/j.eclinm.2023.102294","article-title":"Life expectancy and years of potential life lost in people with mental disorders: a systematic review and meta-analysis","volume":"65","author":"Chan","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2026050903565267000_ref2","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.ahj.2005.02.007","article-title":"Schizophrenia and increased risks of cardiovascular disease","volume":"150","author":"Hennekens CH","year":"2005","journal-title":"Am Heart J."},{"key":"2026050903565267000_ref3","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/wps.20204","article-title":"Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder","volume":"14","author":"Correll CU","year":"2015","journal-title":"World Psychiatry."},{"key":"2026050903565267000_ref4","doi-asserted-by":"publisher","first-page":"573479","DOI":"10.3389\/fendo.2020.573479","article-title":"Impact of psychotropic medication effects on obesity and the metabolic syndrome in people with serious mental illness","volume":"11","author":"Mazereel","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026050903565267000_ref5","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"key":"2026050903565267000_ref6","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"2026050903565267000_ref7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00023210-200519001-00001","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"Newcomer JW","year":"2005","journal-title":"CNS Drugs"},{"key":"2026050903565267000_ref8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1055\/s-0029-1212029","article-title":"Society and personal costs of obesity","volume":"106","author":"Seidell JC","year":"1998","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"2026050903565267000_ref9","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.molmed.2010.10.010","article-title":"Antipsychotic drugs and obesity","volume":"17","author":"Correll CU","year":"2011","journal-title":"Trends Mol Med."},{"key":"2026050903565267000_ref10","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1038\/s41598-018-36930-y","article-title":"Chronic olanzapine administration causes metabolic syndrome through inflammatory cytokines in rodent models of insulin resistance","volume":"9","author":"Li H","year":"2019","journal-title":"Sci Rep"},{"key":"2026050903565267000_ref11","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.csbj.2024.01.003","article-title":"Identification of key modules in metabolic syndrome induced by second-generation antipsychotics based on co-expression network analysis","volume":"23","author":"Sun","year":"2024","journal-title":"Comput Struct Biotechnol J"},{"key":"2026050903565267000_ref12","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.schres.2012.03.017","article-title":"Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials","volume":"140","author":"Caemmerer J","year":"2012","journal-title":"Schizophr Res."},{"key":"2026050903565267000_ref13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/wps.20614","article-title":"The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials","volume":"18","author":"Vancampfort D","year":"2019","journal-title":"World Psychiatry"},{"key":"2026050903565267000_ref14","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1001\/jama.2007.56-b","article-title":"Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial","volume":"299","author":"Wu RR","year":"2008","journal-title":"JAMA"},{"key":"2026050903565267000_ref15","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s40814-018-0378-1","article-title":"Reducing weight gain in people with schizophrenia, schizoaffective disorder, and first episode psychosis: describing the process of developing the STructured lifestyle Education for People With SchizophrEnia (STEPWISE) intervention","volume":"4","author":"Carey","year":"2018","journal-title":"Pilot Feasibility Stud"},{"key":"2026050903565267000_ref16","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1093\/schbul\/sbu030","article-title":"Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis","volume":"40","author":"Mizuno Y","year":"2014","journal-title":"Schizophr Bull"},{"key":"2026050903565267000_ref17","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1038\/npp.2010.21","article-title":"Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis","volume":"35","author":"Maayan","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"2026050903565267000_ref18","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1177\/02698811211035391","article-title":"Efficacy and tolerability of pharmacological interventions on metabolic disturbance induced by atypical antipsychotics in adults: a systematic review and network meta-analysis","volume":"35","author":"Wang Y","year":"2021","journal-title":"J Psychopharmacol"},{"key":"2026050903565267000_ref19","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/schbul\/sbae173","article-title":"The optimal dosage and duration of metformin for prevention and treatment of antipsychotic-induced weight gain: an updated systematic review and meta-analysis","volume":"51","author":"Peng TR","year":"2025","journal-title":"Schizophr Bull."},{"key":"2026050903565267000_ref20","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1001\/jamapsychiatry.2017.1220","article-title":"Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial","volume":"74","author":"Larsen JR","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"2026050903565267000_ref21","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1111\/dom.13167","article-title":"Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: a randomized controlled trial (CODEX)","volume":"20","author":"Siskind","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2026050903565267000_ref22","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1001\/jamapsychiatry.2025.2332","article-title":"Semaglutide treatment of antipsychotic-treated patients with schizophrenia, prediabetes, and obesity: the HISTORI randomized clinical trial","volume":"82","author":"Ganeshalingam AA","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"2026050903565267000_ref23","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1001\/jamainternmed.2013.2720","article-title":"Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study","volume":"173","author":"Singh","year":"2013","journal-title":"JAMA Intern Med"},{"key":"2026050903565267000_ref24","doi-asserted-by":"publisher","first-page":"925377","DOI":"10.3389\/fphar.2022.925377","article-title":"GLP-1 receptor agonist-associated tumor adverse events: a real-world study from 2004 to 2021 based on FAERS","volume":"13","author":"YZ","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026050903565267000_ref25","volume-title":"EMA Statementon Ongoing Review of GLP-1 Receptor Agonists","author":"European Medicines Agency","year":"2023"},{"key":"2026050903565267000_ref26","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jama.2024.2252","article-title":"GLP-1 agonists for obesity\u2014a new recipe forsuccess?","volume":"331","author":"Mozaffarian","year":"2024","journal-title":"JAMA"},{"key":"2026050903565267000_ref27","doi-asserted-by":"publisher","first-page":"706914","DOI":"10.3389\/fendo.2021.706914","article-title":"Sodium-glucose co-transporter-2 inhibitors in non-diabetic adults with overweight or obesity: a systematic review and meta-analysis","volume":"12","author":"Zheng","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026050903565267000_ref28","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jacc.2020.11.008","article-title":"Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction","volume":"77","author":"Santos-Gallego CG","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026050903565267000_ref29","doi-asserted-by":"publisher","first-page":"e019463","DOI":"10.1161\/JAHA.120.019463","article-title":"Effects of sodium\/glucose cotransporter 2 (SGLT2) inhibitors on cardiovascular and metabolic outcomes in patients without diabetes mellitus: a systematic review and meta-analysis of randomized-controlled trials","volume":"10","author":"Teo YH","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026050903565267000_ref30","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3892\/etm.2023.11824","article-title":"Impact of SGLT2 inhibitors on metabolic status in patients with psychiatric disorders undergoing treatment with second-generation antipsychotics (review)","volume":"25","author":"Vasiliu","year":"2023","journal-title":"Exp Ther Med"},{"key":"2026050903565267000_ref31","article-title":"Effect of empagliflozin oncardiometabolic side effects of atypical antipsychotics in patients with psychiatric disorders: a randomized clinical trial","volume":"28","author":"Aminzadeh","year":"2024","journal-title":"Iran Biomed J"},{"key":"2026050903565267000_ref32","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1007\/s40495-020-00236-3","article-title":"SGLT2 inhibitors and the mechanisms involved in weight loss","volume":"6","author":"Feder","year":"2020","journal-title":"Curr Pharmacol Rep"},{"key":"2026050903565267000_ref33","doi-asserted-by":"publisher","first-page":"578716","DOI":"10.3389\/fphar.2021.578716","article-title":"Empagliflozin effectively attenuates olanzapine-induced body weight gain in female Wistar rats","volume":"12","author":"Ashraf","year":"2021","journal-title":"Front Pharmacol"},{"key":"2026050903565267000_ref34","volume-title":"Structured Clinical Interview for DSM-IV Axis I Disorders (SCID I)","author":"First","year":"1997"},{"key":"2026050903565267000_ref35","volume-title":"The Asia-Pacific Perspective: Redefining Obesity and its Treatment","author":"World Health Organization","year":"2000"},{"key":"2026050903565267000_ref36","volume-title":"ECDEU AssessmentManual for Psychopharmacology, Revised","author":"Guy","year":"1976"},{"key":"2026050903565267000_ref37","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0140-6736(03)15268-3","article-title":"Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies","volume":"363","author":"Barba C, Cavalli-Sforza T, Cutter J, Darnton-Hill I, Deurenberg P, Deurenberg-Yap M. WHO Expert Consultation","year":"2004","journal-title":"Lancet"},{"key":"2026050903565267000_ref38","volume-title":"CityBite[Mobile Application Software]","author":"Asia Diabetes Foundation","year":"2020"},{"key":"2026050903565267000_ref39","volume-title":"DietaryGuideline for Weight Management","author":"Hong Kong Dietitians Association","year":"2018"},{"key":"2026050903565267000_ref40","volume-title":"Hong Kong Food ExchangeHandbook","author":"Sea","year":"2007"},{"key":"2026050903565267000_ref41","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay SR","year":"1987","journal-title":"Schizophr Bull"},{"key":"2026050903565267000_ref42","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1161\/CIRCULATIONAHA.118.036568","article-title":"Antihyperglycemic and blood pressure effects of empagliflozin in black patients with type 2 diabetes mellitus and hypertension","volume":"139","author":"Ferdinanad K","year":"2019","journal-title":"Circulation"},{"key":"2026050903565267000_ref43","doi-asserted-by":"publisher","first-page":"109080","DOI":"10.1016\/j.intimp.2022.109080","article-title":"The impact of SGLT2 inhibitors on inflammation: a systematic review and meta-analysis of studies in rodents","volume":"111","author":"Theofilis","year":"2022","journal-title":"Int Immunopharmacol"}],"container-title":["Schizophrenia Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/52\/3\/sbag050\/68257760\/sbag050.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/52\/3\/sbag050\/68257760\/sbag050.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T07:57:04Z","timestamp":1778313424000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article\/doi\/10.1093\/schbul\/sbag050\/8674781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":43,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,5,9]]},"published-print":{"date-parts":[[2026,4,10]]}},"URL":"https:\/\/doi.org\/10.1093\/schbul\/sbag050","relation":{},"ISSN":["0586-7614","1745-1701"],"issn-type":[{"value":"0586-7614","type":"print"},{"value":"1745-1701","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,4,10]]},"article-number":"sbag050"}}